Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma

Gynecologic Oncology

Volumn 108, Issue 1, 2008, Pages 47-52

  Pectasides, Dimitrios ^a   Xiros, Nicolaos ^a   Papaxoinis, George ^a   Aravantinos, Gerasimos ^b   Sykiotis, Constantinos ^a   Pectasides, Erini ^a   Psyrri, Amanda ^a   Koumarianou, Anna ^a   Gaglia, Asimina ^a   Gouveris, Panayiotis ^a   Economopoulos, Theofanis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

Author keywords

Chemotherapy; Cisplatin; Cyclophosphamide; Gemcitabine; Liposomal doxorubicin; Ovarian cancer; Refractory; Resistant

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FUROSEMIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL;

ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; LUNG DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS;

EID: 37449029285     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.08.061     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. du Bois A., Luck H.J., Meier W., Adams H.P., Mobus V., Costa S., et al. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 17 (2003) 1320-1329
3. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 17 (Sep 2003) 3194-3200
4. Markman M., and Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 5 1 (2000) 26-35
5. Papadimitriou C.A., Fountzilas G., Aravantinos G., Kalofonos C., Moulopoulos L.A., Briassoulis E., et al. Hellenic Cooperative Oncology Group study. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group study. Gynecol Oncol 92 1 (Jan 2004) 152-159
6. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 29 (2006) 4699-4707
7. Pfisterer J., and Ledermann J.A. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 33 2 Suppl 6 (2006) S12-S16
8. Markman M. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?. Gynecol Oncol 81 1 (2001) 1-2
9. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 9375 (2003) 2099-2106
10. Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher V., Francis P.A., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63 1 (1996) 89-93
11. Bookman M.A. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15 Suppl 1 (2005) 12-17
12. Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 3 (1997) 987-993
13. Gordon A.N., Granai C.O., Rose P.G., Hainsworth J., Lopez A., Weissman C., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18 17 (2000) 3093-3100
14. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 14 (2001) 3312-3322
15. Mutch D., Orlando M., Teneriello T., Gordon A., McMeekin S., Goss T., et al. Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct). Eur J Cancer Suppl 3 (2005) 262
16. Ferrandina G., Lorusso D., Pignata S., Breda E., Savarese A., Nardi M., et al. The Multicentre Italian Trials in Ovarian Cancer (MITO) Group. A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC). Proc Am Soc Clin Oncol 25 (2007) 18S [abstr 5506]
17. Herzog T.J., Holloway R.W., and Stuart G.C. Workshop: options for therapy in ovarian cancer. Gynecol Oncol 90 3 Pt 2 (2003) S45-S50
18. D'Agostino G., Ferrandina G., Ludovisi M., Testa A., Lorusso D., Gbaguidi N., et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer 89 7 (2003) 1180-1184
19. Skarlos D.V., Kalofonos H.P., Fountzilas G., Dimopoulos M.A., Pavlidis N., Razis E., et al. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res 25 4 (2005) 3103-3108
20. Kavanagh J., Tresukosol D., Edwards C., Freedman R., Gonzalez de Leon C., Fishman A., et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13 7 (1995) 1584-1588
21. Bozas G., Bamias A., Koutsoukou V., Efstathiou E., Gika D., Papadimitriou C.A., et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 104 3 (2007) 580-585
22. Lawton F., Meanwell C., Mould J., and Blackledge G. A five-drug alternating chemotherapy regimen for patients with advanced epithelial ovarian cancer. Gynecol Oncol 36 1 (1990) 19-22
23. Zoli W., Ricotti L., Barzanti F., Dal Susino M., Frassineti G.L., Milandri C., et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 80 3 (1999) 413-416
24. Guppy A.E., and Rustin G.J. CA125 response: can it replace the traditional response criteria in ovarian cancer?. Oncologist 7 5 (2002) 437-443
25. Rustin G.J., Quinn M., Thigpen T., du Bois A., Pujade-Lauraine E., Jakobsen A., et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 92 3 (2000) 205-216
26. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication vol. 48 (1979), Switzerland: World Health Organization, Geneva
27. Simon R., Wittes R.E., and Ellenberg S.S. Randomized phase II clinical trials. Cancer Treat Rep 69 12 (1985) 1375-1381
28. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl 5 (2002) 20-28
29. Kavanagh J.J., and Nicaise C. Carboplatin in refractory epithelial ovarian cancer. Semin Oncol 16 2 Suppl 5 (1989) 45-48
30. Gore M.E., Fryatt I., Wiltshaw E., Dawson T., Robinson B.A., and Calvert A.H. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 60 5 (1989) 767-769
31. Leitao Jr. M.M., Hummer A., Dizon D.S., Aghajanian C., Hensley M., and Sabbatini P. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 91 1 (2003) 123-129
32. Valerio M.R., Tagliaferri P., Raspagliesi F., Fulfaro F., Badalamenti G., Arcara C., et al. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer 16 Suppl 1 (2006) 79-85
33. Petru E., Angleitner-Boubenizek L., Reinthaller A., Deibl M., Zeimet A.G., Volgger B., et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol 102 2 (2006) 226-229
34. Ferrandina G., Paris I., Ludovisi M., D'Agostino G., Testa A., Lorusso D., et al. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol 98 2 (2005) 267-273
35. Rose P.G., Mossbruger K., Fusco N., Smrekar M., Eaton S., and Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88 1 (2003) 17-21
36. Brewer C.A., Blessing J.A., Nagourney R.A., Morgan M., and Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103 2 (2006) 446-450